August 14, 2021
Ayala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
– Enrolled the First Patient in the Phase 2/3 Pivotal Trial of AL102 for the Treatment of Desmoid Tumors –…
Pharmaceuticals, Biotechnology and Life Sciences
– Enrolled the First Patient in the Phase 2/3 Pivotal Trial of AL102 for the Treatment of Desmoid Tumors –…
Continued enrollment in Phase 1/2 trial of first-in-class p53 Y220C reactivator PC14586 CRANBURY, N.J., Aug. 13, 2021 (GLOBE NEWSWIRE) —…
Consolidated Net Revenue of $21.7 Million up 117% vs. Second Quarter of 2020Consolidated Net Product Revenue of $10.7 Million up…
TORONTO, Aug. 13, 2021 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic…
SAN CARLOS, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for…
SEATTLE and CAMBRIDGE, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (NASDAQ: ELYM), a clinical-stage biotechnology company…
Initiated preclinical animal studies for MN-166 as a treatment for chlorine gas-induced induced lung disease under partnership with BARDA Positive…
BRIDGEWATER, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) — Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated…
The exclusively licensed platform has potential application for any tumor target Preclinical development to continue at Mayo Clinic Mustang to…
SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed…